Describe the role for inotropic and vasopressor therapy in acute decompensated right ventricular failure
List some of the limitations of inotropic and vasopressor therapy
Discuss the use of other potential therapies in RV failure
Marc de Perrot, MD, MSc
Division of Thoracic Surgery
University of Toronto
Myung Park, MD
Assistant Professor of Medicine
University of Maryland School of Medicine
Murali Chakinala, MD
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine
St. Louis, Mo.
W. Edwin Dodson, MD
Associate Vice Chancellor and Associate Dean for Admissions and Continuing Medical Education
Professor of Pediatrics and Neurology
Washington University School of Medicine
St. Louis, Mo.
11 April 2014
11 April 2016
This enduring activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Washington University School of Medicine, Continuing Medical Education and the Pulmonary Hypertension Association. Washington University is accredited by the ACCME to provide continuing medical education for physicians.Washington University is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Washington University designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of Washington University School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.
All members of the CME department have nothing to disclose. Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations. Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests. The presenters’ views do not represent the policy or position of Washington University School of Medicine.
This activity is a self-study program. Upon entering the activity, participants should read the text, examine any images and/or multimedia features, and review the content presented within all of the links provided. Once the course has been reviewed in its entirety, participants will be asked to complete a post-test and evaluation online. Participants must receive a test score of 80% in order to proceed to the course evaluation; the post-test can be repeated until all questions are answered correctly. All evaluation questions must be completed in order to receive a certificate of credit. If needed, participants may save their answers and complete the course at a later date. Saved courses can be found by using the "My Courses" link at the top of the page, and then click on "My Classes."
The Accreditation Council for Continuing Medical Education and the Association of American Colleges have standards and guidelines to ensure that individuals participating in CME activities are aware of relationships between authors and commercial companies that could potentially affect the information presented. To be disclosed to participants are all personal financial relationships with a commercial interest whose products are relevant to the content of this CME activity. It is the policy of Washington University School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty participating in this activity are expected to disclose to the audience any financial interest or other potential conflict. Each author was asked to complete a disclosure information form for this activity. Disclosures are reported below:
Marc de Perrot, MD, MSc, indicates that he has served as a consultant for Gilead Pharmaceuticals.
Myung Park, MD, indicates that she has served as a consultant for Actelion, Bayer, Gilead and United Therapeutics and has served on Speakers' Bureaus or received honoraria from Actelion, Bayer, Gilead, United Therapeutics and Pfizer.
Murali Chakinala, MD, indicates that he receives research support or serves as a consultant to Actelion, Gilead, United Therapeutics, Lung LLC, Novartis, and Ikaria.
W. Edwin Dodson, MD, indicates that he has no financial relationship to disclose.
The information presented in this activity reflects the views of the faculty only and not necessarily those of the Pulmonary Hypertension Association (PHA), Washington University in St. Louis, or the educational grant providers. All participants should verify the information and data presented before treating patients or utilizing any therapies noted in these materials. No portion of this activity may be reproduced without the expressed written consent of PHA.
This course requires an internet browser. For optimum display, please use Mozilla Firefox, Safari or Google Chrome.
This activity is made possible through educational grants from Actelion, Gilead, United Therapeutics and Bayer.
©2015 Pulmonary Hypertension Association, 801 Roeder Road, Suite 1000, Silver Spring, MD 21910.